GEO DataSets

(Submitter supplied) Expression profiles of acute myeloid leukemia patient samples. Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of acute myeloid patients. Samples contained 80-100 percent blast cells. Total RNA was extracted by lyses with guanidium isothiocyanate followed by cesium chloride gradient purification Keywords: other

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL96

293 Samples

Download data: CEL

(Submitter supplied) Acute myeloid leukemia (AML) is one of the most common and deadly forms of hematopoietic malignancies. We hypothesized that microarray studies could identify previously unrecognized expression changes that only occur only in AML blasts. We were particularly interested in those genes with increased expression in AML, believing that these genes may be potential therapeutic targets. Keywords: AML vs Normal hematopoietic cells

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS3057

Platform:

GPL96

64 Samples

Download data: CEL

Comparison of leukemic blasts from 26 acute myeloid leukemia (AML) patients with normal hematopoietic cells at a variety of different stages of maturation from 38 healthy donors. Results provide insight into the possible clinical significance of those genes with AML-specific expression changes.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 4 cell type, 2 disease state sets

Platform:

GPL96

Series:

GSE9476

64 Samples

Download data: CEL

(Submitter supplied) Acute myeloid leukemia study. Supplementary Table 1: Clinical, morphological, cytogenetic and molecular genetic information on 116 AML patient samples. Supplementary Table 2: Summary of the distribution of clinical and molecular genetic characteristics within the AML sample set. Supplementary Table 3: Fluorescence ratios of the 6,283 well-measured and variably-expressed genes. Supplementary Table 4: Clinical and laboratory characteristics of normal karyotype predominant subtypes I and II. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Datasets:

GDS841 GDS843

Platforms:

GPL318 GPL319 GPL317

119 Samples

Download data

Part of a study profiling 54 bone marrow and 65 peripheral blood samples from 116 adults with acute myeloid leukemia (AML). Results identify distinct gene expression signatures that correlate with clinical outcomes. Signatures used to construct a clinical outcome predictor using 133 genes.

Organism:

Homo sapiens

Type:

Expression profiling by array, log ratio, 3 disease state, 2 genotype/variation, 2 tissue sets

Platform:

GPL319

Series:

GSE425

49 Samples

Download data

Part of a study profiling 54 bone marrow and 65 peripheral blood samples from 116 adults with acute myeloid leukemia (AML). Results identify distinct gene expression signatures that correlate with clinical outcomes. Signatures used to construct a clinical outcome predictor using 133 genes.

Organism:

Homo sapiens

Type:

Expression profiling by array, log ratio, 2 disease state, 2 genotype/variation, 2 tissue sets

Platform:

GPL317

Series:

GSE425

26 Samples

Download data

(Submitter supplied) Core binding factor (CBF) leukemias, characterized by either inv(16)/t(16;16) or t(8;21), constitute acute myeloid leukemia (AML) subgroups with favorable prognosis. However, there exists substantial biological and clinical heterogeneity within these cytogenetic groups, which is not fully reflected by the current classification system. To improve the molecular characterization we profiled gene expression in a large series (n=93) of AML patients with CBF leukemia [inv(16) n=55, t(8;21) n=38]. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

8 related Platforms

93 Samples

Download data

(Submitter supplied) This data set was used to study FLT3 wild type and mutants in childhood AML samples from the Pediatric Oncology Group Study 9421. Abstract: Fms-like tyrosine kinase 3 (FLT3) mutations are associated with unfavorable outcomes in children with acute myeloid leukemia (AML). We used DNA microarrays to identify gene expression profiles related to FLT3 status and outcome in childhood AML. Among 81 diagnostic specimens, 36 had FLT3 mutations (FLT3-MUs), 24 with internal tandem duplications (ITDs) and 12 with activating loop mutations (ALMs). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

6 related Platforms

87 Samples

Download data

(Submitter supplied) Genome wide DNA methylation profiling of THP1, THP1 expressing WT1 mutant, THP1 expressing IDH2 mutant, CTS cells and AML patient with WT1 mutant. The Illumina Infinium 450K Human DNA methylation Beadchip v1.2 was used to obtain DNA methylation profiles across approximately 485,000 CpGs.

Organism:

Homo sapiens

Type:

Methylation profiling by high throughput sequencing

Platform:

GPL13534

15 Samples

Download data: IDAT

(Submitter supplied) Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology as well as outcome. In this study, we investigated whether known biological subgroups of pediatric AML are reflected by a common microRNA (miRNA) expression pattern. We assayed 665 miRNAs in 165 pediatric AML samples. First, unsupervised clustering was performed to identify patient clusters with common miRNA expression profiles. more...

Organism:

Homo sapiens

Type:

Expression profiling by RT-PCR

Platform:

GPL16566

165 Samples

Download data: TXT

(Submitter supplied) Purpose: CEBPA mutations are found as either biallelic (biCEBPA) or monoallelic (moCEBPA). We set out to explore whether the kind of CEBPA mutation is of prognostic relevance in cytogenetically normal AML (CN-AML). Patients and Methods: 467 homogeneously treated CN-AML patients were subdivided into moCEBPA, biCEBPA and wildtype (wt) CEBPA patients. The subgroups were analyzed for clinical parameters and for additional mutations in the NPM1, FLT3 and MLL genes. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL8289

61 Samples

Download data: CEL

(Submitter supplied) A previously predictive CEBPA double mutant (CEBPAdm) signature was hampered by the recently reported CEBPA silenced AML cases that carry a similar gene expression profile (GEP). Two independent AML cohorts were used to train and evaluate the predictive value of the CEBPAdm signature in terms of sensitivity and specificity. A predictive signature was created, containing 25-probe sets by using a logistic regression model with Lasso regularization, which selects discriminative probe sets between the classes, CEBPAdm and all other AML cases, CEBPA wild type (CEBPAwt) and CEBPA single mutant (CEBPAsm). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4278

Platform:

GPL570

154 Samples

Download data: CEL

(Submitter supplied) Mutations in CCAAT/enhancer binding protein alpha (CEBPA) are seen in 5-14% of acute myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most AMLs with CEBPA mutations simultaneously carry two mutations (CEBPAdouble-mut), usually biallelic, while single heterozygous mutations (CEBPAsingle-mut) are less frequently seen. Using denaturing high performance liquid chromatography and nucleotide sequencing we identified among a cohort of 598 newly diagnosed AMLs a subset of 41 CEBPA mutant cases, i.e. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

526 Samples

Download data: CEL

Analysis of mononuclear cells from bone marrow of untreated AML patients with CCAAT/enhancer binding protein alpha double mutation (CEBPAdm) or single mutation (CEBPAsm). Favorable outcome is observed in AML patients with CEBPAdm. Results provide insight into molecular basis of AML classification.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 5 disease state, 3 genotype/variation sets

Platform:

GPL570

Series:

GSE22845

154 Samples

Download data: CEL

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6947

206 Samples

Download data

(Submitter supplied) Background: Gene expression profiling has shown its ability to identify with high accuracy low cytogenetic risk acute myeloid leukemia such as acute promyelocytic leukemia and leukemias with t(8;21) or inv(16). The aim of this gene expression profiling study was to evaluate to what extent suboptimal samples with low leukemic blast load (range, 2-59%) and/or poor quality control criteria could also be correctly identified. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6947

117 Samples

Download data

(Submitter supplied) Background: Gene expression profiling has shown its ability to identify with high accuracy low cytogenetic risk acute myeloid leukemia such as acute promyelocytic leukemia and leukemias with t(8;21) or inv(16). The aim of this gene expression profiling study was to evaluate to what extent suboptimal samples with low leukemic blast load (range, 2-59%) and/or poor quality control criteria could also be correctly identified. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6947

89 Samples

Download data: TXT

(Submitter supplied) Mononuclear cells from AML patients (n=46) were sorted into CD34+ and CD34- subfractions and genome-wide expression analysis was performed using Illumina BeadChip Arrays (HT12 v3). Of 2 AML samples only the CD34+ fraction could be analyzed. AML CD34+ and CD34- gene expression was compared to a large group of normal CD34+ bone marrow cells (n=31).

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL6947

121 Samples

Download data: TXT

(Submitter supplied) High VEGFC mRNA expression of AML blasts is related to increased in vitro and in vivo drug resistance. The prognostic significance of VEGFC on long-term outcome and its associated gene expression profiles remain to be defined. We studied the effect of VEGFC on treatment outcome and investigated gene expression profiles associated with VEGFC using microarray data of 525 adult and 100 pediatric AML patients. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

98 Samples

Download data: CEL

(Submitter supplied) The pretreatment karyotype of leukemic blasts is currently the key determinant in therapy decision-making in acute myeloid leukemia (AML). However, approximately fifty percent of AML patients, often carrying a normal karyotype, are currently unclassifiable based these established methods. Gene expression profiling has proven to be valuable for risk stratification of AML. The gene expression profiles of AML samples of two independent cohorts (n=247 and n=214) were determined using Affymetrix U133Plus2.0 GeneChips: all Samples below 4000 are in the training cohort; all Samples higher than 4000 are in the validation cohort. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

537 Samples

Download data: CEL